Trial ID or NCT#
NCT02401048
Status
NOT RECRUITING
Purpose
The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in subjects with relapsed or refractory lymphomas.
Official Title
A Multi-Center Open-Label Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Lymphomas
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Lauren Maeda
Hematologist,
Lymphoma specialist,
Hematologist-Oncologist
Clinical Associate Professor, Medicine - Oncology
Clinical Assistant Professor, Medicine - Hematology
Ash A. Alizadeh, MD/PhD
Medical oncologist,
Lymphoma specialist,
Cancer geneticist
Moghadam Family Professor
Michael Khodadoust
Lymphoma specialist,
Cutaneous oncology specialist,
Hematologist,
Hematologist-Oncologist
Assistant Professor of Medicine (Oncology) and of Dermatology
Neel K. Gupta
Hematologist-Oncologist
Clinical Assistant Professor, Medicine - Oncology
Clinical Assistant Professor, Medicine - Hematology
Contact us to find out if this trial is right for you.
CONTACT
Ami Okada
(650) 725-4968
View on ClinicalTrials.gov